| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sergio Vegas-Suárez, Asier Aristieta, Catalina Requejo, Harkaitz Bengoetxea, José Vicente Lafuente, Cristina Miguelez, Luisa Uged. The effect of 5-HT British journal of pharmacology. vol 178. issue 12. 2021-07-05. PMID:33686657. |
the effect of 5-ht l-dopa prolonged treatment leads to disabling motor complications as dyskinesia that could be decreased by drugs acting on 5-ht |
2021-07-05 |
2023-08-13 |
Not clear |
| Feras Altwal, Connor Moon, Anthony R West, Heinz Steine. The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease. Cells. vol 9. issue 10. 2021-07-02. PMID:33050305. |
such dyskinesia is associated with aberrant gene regulation in neurons of the striatum, which is caused by abnormal dopamine release from serotonin terminals. |
2021-07-02 |
2023-08-13 |
rat |
| Feras Altwal, Connor Moon, Anthony R West, Heinz Steine. The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease. Cells. vol 9. issue 10. 2021-07-02. PMID:33050305. |
previous work showed that modulating the striatal serotonin innervation with selective serotonin reuptake inhibitors (ssris) or 5-ht1a receptor agonists could attenuate l-dopa-induced dyskinesia. |
2021-07-02 |
2023-08-13 |
rat |
| Cynthia Kwan, Imane Frouni, Dominique Bédard, Adjia Hamadjida, Philippe Huo. Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat. Behavioural pharmacology. vol 32. issue 1. 2021-06-21. PMID:33399295. |
we have previously demonstrated that serotonin type 3 (5-ht3) receptor blockade with the clinically available and highly selective antagonist ondansetron alleviates dyskinesia in the 6-hydroxydopamine (6-ohda)-lesioned rat. |
2021-06-21 |
2023-08-13 |
rat |
| Ria Fisher, Atsuko Hikima, Rebecca Morris, Michael J Jackson, Sarah Rose, Mark A Varney, Ronan Depoortere, Adrian Newman-Tancred. The selective 5-HT Neuropharmacology. vol 167. 2021-04-23. PMID:32057799. |
the selective 5-ht l-dopa is the gold-standard pharmacotherapy for treatment of parkinson's disease (pd) but can lead to the appearance of troubling dyskinesia which are attributable to 'false neurotransmitter' release of dopamine by serotonergic neurons. |
2021-04-23 |
2023-08-13 |
Not clear |
| Ria Fisher, Atsuko Hikima, Rebecca Morris, Michael J Jackson, Sarah Rose, Mark A Varney, Ronan Depoortere, Adrian Newman-Tancred. The selective 5-HT Neuropharmacology. vol 167. 2021-04-23. PMID:32057799. |
reducing the activity of these neurons diminishes l-dopa-induced dyskinesia (lid), but there are currently no clinically approved selective, high efficacy 5-ht |
2021-04-23 |
2023-08-13 |
Not clear |
| Mélanie Lagière, Marion Bosc, Sara Whitestone, Abdelhamid Benazzouz, Abdeslam Chagraoui, Mark J Millan, Philippe De Deurwaerdèr. A Subset of Purposeless Oral Movements Triggered by Dopaminergic Agonists Is Modulated by 5-HT International journal of molecular sciences. vol 21. issue 22. 2021-03-03. PMID:33198169. |
a subset of purposeless oral movements triggered by dopaminergic agonists is modulated by 5-ht dopaminergic medication for parkinson's disease is associated with troubling dystonia and dyskinesia and, in rodents, dopaminergic agonists likewise induce a variety of orofacial motor responses, certain of which are mimicked by serotonin2c (5-ht |
2021-03-03 |
2023-08-13 |
Not clear |
| Concepció Marin, Mercè Bonastre, Mireya Fuentes, Joaquim Mullo. Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats. Pharmacology, biochemistry, and behavior. vol 197. 2021-02-08. PMID:32750392. |
lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by l-dopa and pramipexole in hemiparkinsonian rats. |
2021-02-08 |
2023-08-13 |
rat |
| Concepció Marin, Mercè Bonastre, Mireya Fuentes, Joaquim Mullo. Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats. Pharmacology, biochemistry, and behavior. vol 197. 2021-02-08. PMID:32750392. |
the role of pallidal serotonergic terminals in the development of l-dopa-induced dyskinesias (lids) in parkinson's disease (pd) has been recently highlighted correlating pallidal serotonin transporter (sert) expression levels with dyskinesias severity. |
2021-02-08 |
2023-08-13 |
rat |
| Cynthia Kwan, Imane Frouni, Dominique Bédard, Adjia Hamadjida, Philippe Huo. Ondansetron, a highly selective 5-HT European journal of pharmacology. vol 871. 2020-11-27. PMID:31926127. |
ondansetron, a highly selective 5-ht l-3,4-dihydroxyphenylalanine (l-dopa) has been the standard treatment for parkinson's disease (pd), despite that its chronic use leads to motor fluctuations and dyskinesia in as many as 95% of patients. |
2020-11-27 |
2023-08-13 |
Not clear |
| Cristina Miguelez, Abdelhamid Benazzouz, Luisa Ugedo, Philippe De Deurwaerdèr. Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications. Frontiers in cellular neuroscience. vol 11. 2020-09-30. PMID:28955204. |
most studies have focused on the fact that l-dopa can be transformed into dopamine (da) and released from 5-ht terminals, which is especially important for the management of l-dopa-induced dyskinesia. |
2020-09-30 |
2023-08-13 |
Not clear |
| Ana Muñoz, Andrea Lopez-Lopez, Carmen M Labandeira, Jose L Labandeira-Garci. Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson's Disease and Adverse Effects of L-DOPA. Frontiers in neuroanatomy. vol 14. 2020-09-28. PMID:32581728. |
this mechanism may also be involved in the development of graft-induced dyskinesias (gid), possibly due to the inclusion of serotonin neurons in the grafted tissue. |
2020-09-28 |
2023-08-13 |
Not clear |
| Sergio Vegas-Suarez, Elena Paredes-Rodriguez, Asier Aristieta, Jose V Lafuente, Cristina Miguelez, Luisa Uged. Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia. International review of neurobiology. vol 146. 2020-02-03. PMID:31349930. |
this review will provide an overview of the underlying mechanisms responsible for 5-ht dysfunction and its clinical relevance in pd and dyskinesia. |
2020-02-03 |
2023-08-13 |
Not clear |
| Adjia Hamadjida, Stephen G Nuara, Jim C Gourdon, Philippe Huo. Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996). vol 125. issue 9. 2019-11-14. PMID:29247391. |
trazodone is a clinically available anti-depressant that exhibits affinity for serotonin 1a and 2a receptors, as well as for alpha-adrenoceptors, suggesting that it may be useful to treat l-3,4-dihydroxyphenylalanine (l-dopa)-induced dyskinesia and psychosis that are encountered in advanced parkinson's disease (pd). |
2019-11-14 |
2023-08-13 |
marmoset |
| Samantha M Meadows, Melissa M Conti, Libby Gross, Nicole E Chambers, Yarden Avnor, Corinne Y Ostock, Kathryn Lanza, Christopher Bisho. Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats. Movement disorders : official journal of the Movement Disorder Society. vol 33. issue 11. 2019-09-16. PMID:30485908. |
diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats. |
2019-09-16 |
2023-08-13 |
rat |
| Cynthia Kwan, Imane Frouni, Dominique Bédard, Stephen G Nuara, Jim C Gourdon, Adjia Hamadjida, Philippe Huo. 5-HT Experimental brain research. vol 237. issue 2. 2019-06-03. PMID:30443669. |
5-ht virtually every patient affected by parkinson's disease (pd) eventually requires treatment with l-3,4-dihydroxyphenylalanine (l-dopa), which leads to complications such as dyskinesia and psychosis. |
2019-06-03 |
2023-08-13 |
Not clear |
| Imane Frouni, Cynthia Kwan, Dominique Bédard, Sébastien Belliveau, Élodie Bourgeois-Cayer, Fleur Gaudette, Francis Beaudry, Adjia Hamadjida, Philippe Huo. Effect of the selective 5-HT Experimental brain research. vol 237. issue 1. 2019-05-10. PMID:30298296. |
effect of the selective 5-ht l-3,4-dihydroxyphenylalanine (l-dopa) is the most effective therapy for motor symptoms of parkinson's disease (pd); however, with repeated administration, as many as 94% of pd patients develop complications such as l-dopa-induced dyskinesia. |
2019-05-10 |
2023-08-13 |
Not clear |
| Adrian Newman-Tancredi, Mark A Varney, Andrew C McCrear. Effects of the Serotonin 5-HT Neurochemical research. vol 43. issue 5. 2018-09-27. PMID:29572645. |
effects of the serotonin 5-ht peak-dose dyskinesia is associated with the dramatic increase in striatal dopamine levels that follows l-dopa administration. |
2018-09-27 |
2023-08-13 |
Not clear |
| Philippe Huot, Véronique Sgambato-Faure, Susan H Fox, Andrew C McCrear. Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update. ACS chemical neuroscience. vol 8. issue 5. 2018-02-07. PMID:28460160. |
5-ht also seems to play a critical role in l-3,4-dihydroxyphenylalanine (l-dopa)-induced dyskinesia. |
2018-02-07 |
2023-08-13 |
Not clear |
| Elisabetta Tronci, Francesco Napolitano, Ana Muñoz, Camino Fidalgo, Francesca Rossi, Anders Björklund, Alessandro Usiello, Manolo Cart. BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. Experimental neurology. vol 297. 2017-10-05. PMID:28757258. |
bdnf over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-dopa-induced dyskinesia in 6-ohda-lesioned rats. |
2017-10-05 |
2023-08-13 |
rat |